RxDoctor Payments Data

Harrison Bannett, DO

Ophthalmology · Woodbury, NJNPI 1851898381

Payments from drug & device makers

$4,704in general payments, 2019–2025

Across 65 payments — averaging $72.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$867
  • Mallinckrodt Hospital Products Inc.$237
  • Sight Sciences, Inc.$211
  • Johnson & Johnson Surgical Vision, Inc.$125
  • Amgen$125
  • plus $655 from 15 others

What the payments were for

  • Travel & lodging$1,22526%
  • Food & beverage$3,47974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,704 in reported general payments places this provider in the 80th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$254,204
Medicare patients
384
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast36$38,433
RestasisCyclosporine24$27,198
LumiganBimatoprost32$22,106
RhopressaNetarsudil Mesylate29$14,458
VyzultaLatanoprostene Bunod24$12,493
Prednisolone Acetate191$8,934
RocklatanNetarsudil Mesylat/Latanoprost15$8,878
Cyclosporine13$8,256
ProlensaBromfenac Sodium20$6,886
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$5,015
Bromfenac Sodium19$4,475
Alphagan PBrimonidine Tartrate14$3,819
SimbrinzaBrinzolamide/Brimonidine Tart14$3,638
Latanoprost242$2,555
Timolol Maleate88$2,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$867$53,12470 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$30$50,92660 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$107$8,49831 claims
AlconSimbrinza$2,485$3,63814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Woodbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →